

P01-165

## THE EFFECTS OF OLANZAPINE IN TREATMENT OF PANIC DISORDER WITH AND WITHOUT AGORAPHOBIA

N. Mokhber<sup>1</sup>, F. Savadkoohi<sup>2</sup>, Psychiatry and Behavioural Science Research Centre

<sup>1</sup>Mashad University of Medical Sciences, <sup>2</sup>MUMS, Mashad, Iran

**Background:** In this study, we have evaluated the effects of Olanzapine in treatment of panic disorder with and without agoraphobia.

**Method and materials:** Patients with resistant panic disorder (resistant to two SSRI agents) who came to psychiatric clinic of Ibn-e-Sina and Ghaem Hospitals-Mashhad during 2004-2005 were enrolled in this study. Low dose Olanzapine (2.5 milligram per day) was administered initially. ALL cases were evaluated by different psychiatric tests such as agoraphobic cognitions questionnaire panic attack and anticipatory anxiety scale, Hamilton depression test and general functional assessment.

**Results:** In this study, 30 patients were divided into two groups of panic disorder with agoraphobia (13 cases) and panic disorder without agoraphobia (17 cases). Comparing these two groups, all indexes were improved significantly by time but the frequency of panic attacks in the last week, minor panic attack duration, duration of panic attacks, agoraphobic cognition scale and Hamilton depression indexes were improved significantly especially in those cases with panic disorder and agoraphobia. Although the therapeutic response according to anxiety score, total panic attacks, Hamilton depression test and general functional assessment was not shown any difference.

**Conclusion:** Olanzapine augmentation has acceptable effects in the treatment of drug resistant panic disorder with agoraphobia and therapeutic effects were more significant among patients with panic disorder without agoraphobia.